Brokerages Set Novogen Limited (NASDAQ:KZIA) PT at $25.80

Novogen Limited (NASDAQ:KZIA) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $25.80.

KZIA has been the topic of a number of research reports. Laidlaw initiated coverage on Novogen in a research report on Wednesday, April 15th. They set a “buy” rating and a $25.00 price objective on the stock. Lake Street Capital started coverage on Novogen in a research report on Thursday, June 11th. They issued a “buy” rating and a $32.00 target price for the company. BTIG Research assumed coverage on Novogen in a research note on Wednesday, July 1st. They set a “buy” rating and a $34.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st.

Novogen Stock Performance

Shares of NASDAQ:KZIA opened at $13.56 on Monday. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40. The company has a fifty day moving average of $13.21 and a 200-day moving average of $9.61.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.